Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 PR Newswire - Wed Mar 11, 8:19AM CDT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options

RARE : 21.83 (-4.42%)
LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION PR Newswire - Wed Mar 11, 8:00AM CDT

Important Information Regarding Section 20(a) Individual Liability Claims

RARE : 21.83 (-4.42%)
Investors who lost money on Ultragenyx Pharmaceutical Inc.(RARE) should contact The Gross Law Firm about pending Class Action - RARE PR Newswire - Tue Mar 10, 8:00AM CDT

NEW YORK , March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).

RARE : 21.83 (-4.42%)
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit PR Newswire - Mon Mar 9, 4:59PM CDT

NEW YORK , March 9, 2026 /PRNewswire/ --

RARE : 21.83 (-4.42%)
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors with Losses to Contact the Firm PR Newswire - Sun Mar 8, 11:00AM CDT

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?

RARE : 21.83 (-4.42%)
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE PR Newswire - Fri Mar 6, 8:49PM CST

NEW ORLEANS , March 6, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications...

RARE : 21.83 (-4.42%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE PR Newswire - Thu Mar 5, 3:59PM CST

NEW YORK , March 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE)....

RARE : 21.83 (-4.42%)
Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law PR Newswire - Wed Mar 4, 3:15PM CST

SAN DIEGO , March 4, 2026 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August...

RARE : 21.83 (-4.42%)
LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE PR Newswire - Wed Mar 4, 8:00AM CST

Alert: Claims Focus on Alleged Misrepresentations About Setrusumab Efficacy Potential

RARE : 21.83 (-4.42%)
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit PR Newswire - Tue Mar 3, 3:10PM CST

NEW YORK , March 3, 2026 /PRNewswire/ --

RARE : 21.83 (-4.42%)

Barchart Exclusives

Should You Buy Vertiv Stock Before March 23? Barchart - 3 minutes ago
Vertiv stock surged to an all-time high on news of its inclusion in the S&P 500. Here's what investors need to know. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot